United States · FDA National Drug Code directory
KRAZATI
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 80739-812_65724d4c-78ab-4d85-83b5-73b9da5c2cc3
- Product NDC
- 80739-812
- Form
- TABLET, COATED
- Composition / generic term
- adagrasib
- Labeler
- Mirati Therapeutics, Inc
- Marketing category
- NDA
- Marketing start / end (source format)
- 20221212
- Source listing expiry
- 20271231
Source-listed ingredients
- ADAGRASIB — 200 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 1 BOTTLE in 1 CARTON (80739-812-12) / 120 TABLET, COATED in 1 BOTTLE · 80739-812-12
- 1 BOTTLE in 1 CARTON (80739-812-18) / 180 TABLET, COATED in 1 BOTTLE · 80739-812-18
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →